An adjuvanted, postfusion F protein-based vaccine did not prevent respiratory syncytial virus illness in older adults

Journal of Infectious Diseases

Volumn 216, Issue 11, 2017, Pages 1362-1370

  Falloon, Judith ^a   Yu, Jing ^a   Esser, Mark T ^a   Villafana, Tonya ^a   Yu, Li ^a   Dubovsky, Filip ^a   Takas, Therese ^a   Levin, Myron J ^b   Falsey, Ann R ^c  

^a MEDIMMUNE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Adjuvant; Clinical trial; Efcacy; Respiratory syncytial virus; Subunit; Vaccine

Indexed keywords

ANTIBODY; GLUCOPYRANOSYL LIPID; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; PLACEBO; POSTFUSION F ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; F PROTEIN, HUMAN RESPIRATORY SYNCYTIAL VIRUS; GLUCOPYRANOSYL LIPID-A; GLUCOSIDE; IMMUNOGLOBULIN G; LIPID A; NEUTRALIZING ANTIBODY; PHARMACEUTICAL VEHICLES AND ADDITIVES; VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS FUSION PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EMULSION; FEMALE; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; HUMORAL IMMUNITY; IMMUNOGENICITY; INCIDENCE; MIDDLE AGED; NOSE SMEAR; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIROLOGY; AGED; ANTIBODY PRODUCTION; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; MALE;

ADJUVANTS, IMMUNOLOGIC; ADJUVANTS, PHARMACEUTIC; AGED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; ANTIGENS, VIRAL; DOUBLE-BLIND METHOD; FEMALE; GLUCOSIDES; HUMANS; IMMUNOGLOBULIN G; INFLUENZA VACCINES; LIPID A; MALE; MIDDLE AGED; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VIRAL FUSION PROTEINS;

EID: 85038641593     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix503     Document Type: Article

References (36)

1. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352:1749-59.
2. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991; 163:693-8.
3. Falsey AR, Walsh EE. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J Infect Dis 1998; 177:463-6.
4. Malloy AMW, Falsey AR, Ruckwardt TJ. Consequences of immature and senescent immune responses for infection with respiratory syncytial virus. In: Anderson LJ, Graham BS, eds. Challenges and opportunities for respiratory syn-cytial virus vaccines. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013:211-231.
5. Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis 2004; 189:233-8.
6. Cherukuri A, Patton K, Gasser RA Jr, et al. Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein. Clin Vaccine Immunol 2013; 20:239-47.
7. Graham BS, Modjarrad K, McLellan JS. Novel antigens for RSV vaccines. Curr Opin Immunol 2015; 35:30-8.
8. Langley JM, Aggarwal N, Toma A, et al. A randomized, controlled, observer-blinded phase 1 study of the safety and immunogenicity of a respiratory syncytial virus vaccine with or without alum adjuvant. J Infect Dis 2017; 215:24-33.
9. Melero JA, Mas V, McLellan JS. Structural, antigenic and immu-nogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development. Vaccine 2017; 35:461-8.
10. Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 2011; 162:80-99.
11. Lambert SL, Yang CF, Liu Z, et al. Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant glucopyranosyl lipid A. PLoS One 2012; 7:e51618.
12. Falloon J, Ji F, Curtis C, et al. A phase 1a, frst-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant. Vaccine 2016; 34:2847-54.
13. Falloon J, Talbot K, Curtis C, et al. Dose selection for an adjuvanted respiratory syncytial virus F protein vaccine for older adults based on humoral and cellular immune responses. Clin Vaccine Immunol 2017. In press. doi: 10.1128/CVI.00157-17.
14. Lambert SL, Aslam S, Stillman E, et al. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models. PLoS One 2015; 10:e0119509.
15. Patton K, Aslam S, Shambaugh C, et al. Enhanced immu-nogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomol-gus macaques. Vaccine 2015; 33:4472-8.
16. Powers JH, Guerrero ML, Leidy NK, et al. Development of the Flu-PRO: a patient-reported outcome (PRO) instrument to evaluate symptoms of infuenza. BMC Infect Dis 2016; 16:1.
17. Powers JH, Stringer S, Cliford S, et al. Development of the patient-reported outcome (PRO) instrument FLU-PRO to standardize and quantify symptoms of infuenza. Presented at: 2nd Joint Meeting of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, and the Pediatric Infectious Diseases Society, IDWeek 2013: Advancing Science, Improving Care, San Francisco, CA, 2-6 October 2013.
18. Maifeld SV, Ro B, Mok H, et al. Development of electro-chemiluminescent serology assays to measure the humoral response to antigens of respiratory syncytial virus. PLoS One 2016; 11:e0153019.
19. Patton K, Aslam S, Lin J, et al. Enzyme-linked immunospot assay for detection of human respiratory syncytial virus f protein-specifc gamma interferon-producing T cells. Clin Vaccine Immunol 2014; 21:628-35.
20. McClure DL, Kieke BA, Sundaram ME, et al. Seasonal incidence of medically attended respiratory syncytial virus infection in a community cohort of adults ≥50 years old. PLoS One 2014; 9:e102586.
21. Centers for Disease Control and Prevention (CDC). People at high risk of developing fu-related complications. http://www.cdc.gov/fu/about/disease/high-risk.htm. Accessed 5 August 2016.
22. Grohskopf LA, Shay DK, Shimabukuro T T, et al. Prevention and control of seasonal infuenza with vaccines: recommendations of the Advisory Committee on Immunization Practices-United States, 2013-2014. MMWR Morb Mortal Wkly Rep 2014; 63:691-7.
23. Breslow NE, Day NE. Statistical methods in cancer research. Volume II-the design and analysis of cohort studies. IARC Sci Publ 1987; 82:1-406.
24. Chan ISF, Bohidar NR. Exact power and sample size for vaccine efcacy studies. Commun Stat Teory Methods 1998; 27:1305-22.
25. Duvvuri VR, Granados A, Rosenfeld P, Bahl J, Eshaghi A, Gubbay JB. Genetic diversity and evolutionary insights of respiratory syncytial virus A ON1 genotype: global and local transmission dynamics. Sci Rep 2015; 5:14268.
26. Trento A, Casas I, Calderón A, et al. Ten years of global evolution of the human respiratory syncytial virus BA genotype with a 60-nucleotide duplication in the G protein gene. J Virol 2010; 84:7500-12.
27. Falsey AR, Singh HK, Walsh EE. Serum antibody decay in adults following natural respiratory syncytial virus infection. J Med Virol 2006; 78:1493-7.
28. Walsh EE, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis 2004; 190:373-8.
29. McLellan JS, Yang Y, Graham BS, Kwong PD. Structure of respiratory syncytial virus fusion glycoprotein in the post-fusion conformation reveals preservation of neutralizing epitopes. J Virol 2011; 85:7788-96.
30. Fuentes S, Coyle EM, Beeler J, Golding H, Khurana S. Antigenic fngerprinting following primary RSV infection in young children identifes novel antigenic sites and reveals unlinked evolution of human antibody repertoires to fusion and attachment glycoproteins. PLoS Pathog 2016; 12:e1005554.
31. Ngwuta JO, Chen M, Modjarrad K, et al. Prefusion F-specifc antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med 2015; 7:309ra162.
32. O'Brien KL, Chandran A, Weatherholtz R, et al.; Respiratory Syncytial Virus (RSV) Prevention study group. Efcacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. Lancet Infect Dis 2015; 15:1398-408.
33. Bloom-Feshbach K, Alonso WJ, Charu V, et al. Latitudinal variations in seasonal activity of infuenza and respiratory syncytial virus (RSV): a global comparative review. PLoS One 2013; 8:e54445.
34. Falsey AR, Walsh EE, Capellan J, et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines-nonadjuvanted vaccine or vaccine adju-vanted with alum-given concomitantly with infuenza vaccine to high-risk elderly individuals. J Infect Dis 2008; 198:1317-26.
35. Schuster JE, Cox RG, Hastings AK, et al. A broadly neutralizing human monoclonal antibody exhibits in vivo efcacy against both human metapneumovirus and respiratory syn-cytial virus. J Infect Dis 2015; 211:216-25.
36. Wen X, Mousa JJ, Bates JT, Lamb RA, Crowe JE Jr, Jardetzky TS. Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus. Nat Microbiol 2017; 2:16272.